Cleveland Clinic guidance advises against microdosing GLP-1 medications

Cleveland Clinic published consumer guidance on July 31, 2026 that advises against microdosing GLP-1 medications, saying the practice carries dosing-error risk and has not been shown to produce meaningful or lasting benefit ^[1]. The guidance comes from obesity medicine subspecialist W. Scott Butsch, MD, and covers semaglutide (sold as Wegovy, Ozempic and Rybelsus) and tirzepatide (Mounjaro and Zepbound) ^[1].

Microdosing means intentionally taking less of the drug than prescribed. Cleveland Clinic gives the example of someone with a prescription for 15 milligrams of Mounjaro who takes only part of that amount ^[1]. The idea first drew attention during obesity drug shortages after the medications' FDA approvals in 2021 and 2022, and attention has since shifted to microdosing compounded versions of the drugs ^[1].

Butsch said reduced dosing can bring back side effects that normally fade. "If you take a reduced dose, you run the risk of the drug disappearing from your system faster than intended," he said. "And when you take it again, you're going to have that side effect again because there hasn't been a steady amount of the medication in your system" ^[1]. Common GLP-1 side effects include diarrhea, nausea and bloating, which Cleveland Clinic says often go away within the first day or two when the medication is taken as prescribed ^[1].

Dosing errors are a second concern, especially with compounded products. FDA has received reports of adverse events, some requiring hospitalization, that may be related to overdoses from dosing errors with compounded injectable semaglutide ^[2]. Most of those reports described patients drawing more than the prescribed dose from a multiple-dose vial; in those cases, patients took five to 20 times the intended amount ^[2]. In one example, patients told to inject 5 units instead administered 50 units ^[2]. In another, a provider who meant to prescribe 0.25 milligrams (5 units) wrote 25 units, and a patient took five times the intended dose and had severe vomiting ^[2]. A separate error — 20 units instead of 2 units — affected three patients who received 10 times the intended dose and experienced nausea and vomiting ^[2].

Reported overdose effects include nausea, vomiting, abdominal pain, fainting, headache, migraine, dehydration, acute pancreatitis and gallstones ^[2]. FDA notes that semaglutide has a half-life of about one week, so a prolonged period of observation and treatment may be needed after an overdose ^[2]. Compounded drugs are not reviewed by FDA for safety, quality or effectiveness before they are marketed, and the agency says they should be used only when a patient's medical needs cannot be met by an available FDA-approved drug ^[1][2]. FDA-approved semaglutide injections come in pre-filled pens that deliver a preset or single-patient dose, while compounded versions are sold in varying concentrations and containers ^[2].

Cost is the main reason people try microdosing, according to Cleveland Clinic. Most insurance companies do not cover GLP-1s, prices have dropped to around $500 per month through manufacturers' direct-to-consumer programs, and studies show people who stop taking GLP-1s may regain the weight they lost ^[1].

Why it matters for patients

Microdosing is not an established medical practice. Cleveland Clinic says there are no official or standard guidelines for microdosing GLP-1s, and that the practice is not endorsed by the American Diabetes Association ^[1]. It also says there is not enough research to understand the effectiveness or safety of microdosing compounded GLP-1s ^[1].

That leaves patients weighing an unproven approach against a documented error risk. Because approved semaglutide and tirzepatide products are dosed in milligrams and dispensed in pre-filled pens, taking a fraction of a dose usually means measuring from a compounded vial, where confusion between milligrams, milliliters and "units" has led to fivefold, tenfold and larger overdoses ^[2]. Butsch also said he does not recommend compounded versions of these medications because they are untested for both effectiveness and safety ^[1].

Cleveland Clinic frames clinician-guided dose changes as separate from microdosing. "Like with any other medication, doctors can adjust GLP-1s based on their effectiveness, tolerability or side effects," Butsch said. "We can adjust the dose to the individual needs of each person. And that's not microdosing — that's just the art of practicing medicine" ^[1].

What happens next

No new FDA action or guideline update was announced alongside the Cleveland Clinic guidance, and no dated milestone for future guidance has been disclosed. FDA encourages patients with questions about measuring a compounded semaglutide dose to consult their health care provider or compounder, and asks that adverse events and medication errors be reported through its MedWatch program ^[2].